As part of the Senior Executive Team, I lead Biopharmaceuticals R&D which focuses on Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology and, opportunistically, Neuroscience and Microbial Science.We recently transformed our R&D into two therapy-focused organisations - Biopharmaceuticals R&D and Oncology R&D - to lead all our work from drug discovery through to launch.We share 13 functions specialising in key scientific capabilities from medicinal chemistry to biometrics, patient safety to data science and artificial intelligence (AI), and clinical innovation to device technology, all of which helps us accelerate the discovery, development and delivery of life-changing medicines to the people who need them most.One of my proudest achievements is helping create our 5R framework which guides our drug discovery and development by championing quality over quantity. This has led to the proportion of pipeline molecules advancing from pre-clinical investigation to completion of Phase III clinical trials from 4% to 19% in just five years.Our R&D culture is another huge source of pride for me. Everything we do is about inspiring people with curious minds who are free from failure, free to ask the right questions and free to make bold decisions. We ensure we work seamlessly and inclusively, that our doors are always open and our scientists can work in a permeable research environment, sharing ideas and collaborating with others. We are always harnessing the latest data and technology to fast-forward the pace of our science to help us achieve the next wave of breakthrough therapies.To do this, it is vital we continue to attract the brightest minds, the best talent and the boldest innovators – the people who share our passion for science and our belief in its potential to redefine the possible in order to have the greatest and swiftest impact on disease.

My job is to provide assurance to the board about the quality, competitiveness and integrity of the discovery and development of drugs.

I led AstraZeneca’s small molecule research and early development activities.

I was responsible for 200 scientists and clinicians taking Pfizer neuroscience programmes from target identification through to proof of concept.

I was responsible for overseeing the transition of more than 20 novel drug candidates into clinical development for a number of neurological and psychiatric diseases, including Alzheimer's disease, stroke, schizophrenia, and pain.